Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M11,103Revenue $M1,134Net Margin (%)-36.6Altman Z-Score1.3
Enterprise Value $M13,424EPS $-6.5Operating Margin %-43.2Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-58.5Higher ROA y-yN
Price/Book46.210-y EBITDA Growth Rate %--Quick Ratio0.6Cash flow > EarningsY
Price/Sales10.25-y EBITDA Growth Rate %--Current Ratio0.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-195.1ROA % (ttm)-9.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-71.0Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M63.7ROIC % (ttm)-11.5Gross Margin Increase y-yN

Gurus Latest Trades with SLXP

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SLXPMario Gabelli 2015-03-31 Buy 0.4%$112.84 - $172.81
($146.8)
$ 172.8118%New holding442,350
SLXPGeorge Soros 2015-03-31 Reduce-0.37%$112.84 - $172.81
($146.8)
$ 172.8118%Reduce 58.92%201,903
SLXPFirst Eagle Investment 2015-03-31 Buy 0.2%$112.84 - $172.81
($146.8)
$ 172.8118%New holding479,891
SLXPJohn Paulson 2015-03-31 Reduce-0.18%$112.84 - $172.81
($146.8)
$ 172.8118%Reduce 5.27%5,500,000
SLXPRuane Cunniff 2015-03-31 Buy 0.02%$112.84 - $172.81
($146.8)
$ 172.8118%New holding20,000
SLXPJohn Paulson 2014-12-31 Buy 3.4%$91.47 - $152.87
($120.33)
$ 172.8144%New holding5,806,000
SLXPGeorge Soros 2014-12-31 Buy 0.62%$91.47 - $152.87
($120.33)
$ 172.8144%New holding491,531
SLXPVanguard Health Care Fund 2014-12-31 Sold Out -0.61%$91.47 - $152.87
($120.73)
$ 172.8143%Sold Out0
SLXPVanguard Health Care Fund 2014-09-30 Reduce-0.09%$127.75 - $169.17
($144.97)
$ 172.8119%Reduce 15.70%1,538,045
SLXPJoel Greenblatt 2014-06-30 Sold Out -0.48%$97.7 - $125.07
($110.33)
$ 172.8157%Sold Out0
SLXPVanguard Health Care Fund 2014-06-30 Reduce-0.06%$97.7 - $125.07
($110.42)
$ 172.8157%Reduce 10.25%1,824,545
SLXPJoel Greenblatt 2014-03-31 Buy 0.48%$88.8 - $114.64
($101.95)
$ 172.8170%New holding307,445
SLXPVanguard Health Care Fund 2014-03-31 Reduce-0.03%$89.09 - $114.64
($102.39)
$ 172.8169%Reduce 5.36%2,032,845
SLXPJoel Greenblatt 2013-09-30 Sold Out -0.36%$65.73 - $75.54
($68.97)
$ 172.81151%Sold Out0
SLXPJoel Greenblatt 2013-06-30 Buy 0.36%$47.72 - $66.83
($57.19)
$ 172.81202%New holding127,495
SLXPJoel Greenblatt 2013-03-31 Sold Out -0.15%$40.472 - $51.37
($47.96)
$ 172.81260%Sold Out0
SLXPVanguard Health Care Fund 2013-03-31 Add0.08%$40.472 - $51.37
($47.96)
$ 172.81260%Add 22.44%2,147,945
SLXPNWQ Managers 2012-12-31 Sold Out -0.17%$37.97 - $42.9
($40.82)
$ 172.81323%Sold Out0
SLXPJoel Greenblatt 2012-12-31 Add0.06%$37.97 - $42.9
($40.82)
$ 172.81323%Add 75.81%63,399
SLXPVanguard Health Care Fund 2012-12-31 Add0.02%$37.97 - $42.9
($40.81)
$ 172.81323%Add 12.87%1,754,300
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SLXP is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SLXP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Forbes William PPresident, Medical R&D and CDO 2015-03-09Sell42,880$157.849.48view
CREECH TIMOTHY JSee Remarks 2015-03-06Sell4,600$157.679.6view
Scruggs Rick DExecutive Vice President 2015-03-06Sell4,000$157.559.69view
Forbes William PEVP Research&Devel & CDO 2015-03-06Sell20,000$157.969.4view
Forbes William PEVP Research&Devel & CDO 2014-11-12Sell11,079$95.0581.81view
CREECH TIMOTHY JSee Remarks 2014-11-05Sell0$081.81view
LOGAN CAROLYN JPresident & CEO 2014-06-26Sell53,057$123.3840.06view
Scruggs Rick DExecutive Vice President 2014-05-16Sell900$105.6763.54view
D ALONZO THOMASDirector 2014-04-22Sell11,530$110.8955.84view
CHAPPELL JOHN FDirector 2014-03-04Sell10,000$112.254.02view

Press Releases about SLXP :

Quarterly/Annual Reports about SLXP:

News about SLXP:

Articles On GuruFocus.com
Ruane Cunniff Adds New Positions to Portfolio In Q1FY15 May 18 2015 
Locust Wood Capital Bet on Top Performer Valeant Pharmaceuticals May 14 2015 
Jean-Marie Eveillard Buys Flowserve, W W Grainger May 11 2015 
Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
This Week’s Pharma Highlights Mar 19 2015 
Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
Valeant Pharma Acquires Salix Mar 18 2015 
Looking Ahead of Wall Street: Salix Pharmaceuticals, Receptos, Tetraphase Mar 02 2015 
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
John Paulson's Top Buys Feb 21 2015 

More From Other Websites
Valeant Pharmaceuticals (VRX) Earnings Report: Q2 2015 Conference Call Transcript Jul 23 2015
Valeant profit beats estimates as U.S. sales stay strong Jul 23 2015
Owners of prominent Raleigh office building to test crowdfunding for real estate Jul 15 2015
Valeant Shouldn’t Overfarm Deal Field Jun 26 2015
Raleigh's BioDelivery hires former Salix sales workers May 29 2015
Valeant Pharmaceuticals Gets FDA Nod for Xifaxan for IBS-D - Analyst Blog May 28 2015
FDA Clears Two Irritable Bowel Syndrome Treatments May 27 2015
After Salix acquisition, Valeant receives FDA approval for IBS-D drug May 27 2015
Ruane Cunniff Adds New Positions to Portfolio In Q1FY15 May 18 2015
Drug maker Endo strikes again with $8bn bid for US rival May 18 2015
More Waves In Pharma: Endo Buys TPG Capital's Par Pharma for $8 Billion May 18 2015
John Paulson Buys Actavis, AIG, Valeant, Sells Equinix, Alibaba May 16 2015
Big name investors take sides on Ackman bet on Valeant: filings May 15 2015
JetBlue Airways Corporation (JBLU), Twenty-First Century Fox Inc (FOX): CQS Cayman’s Top Picks for... May 14 2015
Viking Global's Shareholder Letter Talks New Positions In Google, Cheniere, Biggest Winners & Losers May 01 2015
Valeant Pharmaceuticals Reports In-Line Earnings, Ups View - Analyst Blog May 01 2015
Valeant Pharmaceuticals (VRX) Earnings Report: Q1 2015 Conference Call Transcript Apr 30 2015
Valeant Beats Q1 Views, Lifts Guidance, Loses CFO Apr 29 2015
Valeant raises outlook after completing purchase of Salix Apr 29 2015
Valeant raises outlook after completing purchase of Salix Apr 29 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK